TY - JOUR
T1 - Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer
AU - Booser, Daniel J.
AU - Esteva, Francisco J.
AU - Rivera, Edgardo
AU - Valero, Vicente
AU - Esparza-Guerra, Laura
AU - Priebe, Waldemar
AU - Hortobagyi, Gabriel N.
N1 - Funding Information:
D.J.B. was supported by a grant from Aronex Pharmaceuticals, Inc., The Woodlands, Texas.
PY - 2002
Y1 - 2002
N2 - Liposomal annamycin (L-AN) has shown antitumor activity in preclinical studies. It may selectively target tumors and bypass MDR-1 resistance. A total of 13 women with doxorubicin-resistant breast cancer were treated on this phase II study. The median number of prior chemotherapy regimens was two, and six patients had two or more organ sites of involvement. L-AN was administered at 190-250 mg/m2 as an i.v. infusion over 1-2 h every 3 weeks. No responses were observed. Of the 13 patients, 12 had clear deterioration and new tumor growth after one or two courses. The 13th patient had prolonged grade 2 thrombocytopenia after one course, and was taken off study when the lung metastases increased 62 days after treatment. L-AN at this dose and on this schedule had no detectable antitumor activity in patients with doxorubicin-resistant metastatic breast cancer.
AB - Liposomal annamycin (L-AN) has shown antitumor activity in preclinical studies. It may selectively target tumors and bypass MDR-1 resistance. A total of 13 women with doxorubicin-resistant breast cancer were treated on this phase II study. The median number of prior chemotherapy regimens was two, and six patients had two or more organ sites of involvement. L-AN was administered at 190-250 mg/m2 as an i.v. infusion over 1-2 h every 3 weeks. No responses were observed. Of the 13 patients, 12 had clear deterioration and new tumor growth after one or two courses. The 13th patient had prolonged grade 2 thrombocytopenia after one course, and was taken off study when the lung metastases increased 62 days after treatment. L-AN at this dose and on this schedule had no detectable antitumor activity in patients with doxorubicin-resistant metastatic breast cancer.
KW - Annamycin
KW - Anthracycline
KW - Resistant breast cancer
UR - http://www.scopus.com/inward/record.url?scp=0036308763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036308763&partnerID=8YFLogxK
U2 - 10.1007/s00280-002-0464-0
DO - 10.1007/s00280-002-0464-0
M3 - Article
C2 - 12111105
AN - SCOPUS:0036308763
SN - 0344-5704
VL - 50
SP - 6
EP - 8
JO - Cancer chemotherapy and pharmacology
JF - Cancer chemotherapy and pharmacology
IS - 1
ER -